Method for detecting DLX1 mRNA, HOXC6 mRNA, and KLK3 mRNA in a urine sample and predicting and treating clinically significant prostate cancer
View Patent ↗The present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer based on expression analysis of normalized prostate tumor markers. The present methods, devices, combinations, kits, and systems are especially suitable for predicting and treating prostate cancer with a Gleason score of seven or more in individuals with a serum prostate-specific antigen (sPSA) level lower than 15 ng/ml. Specifically, the present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer, the method comprises the steps of: a) determining mRNA expression levels of one or more of the genes DLX1, HOXC6, TDRD1 and KLK3 in a urine sample of said individual; b) normalizing the mRNA expression levels of one ore more of DLX1, HOXC6, and TDRD1 using the mRNA expression level of KLK3; and c) establishing clinically significant prostate cancer based on a combination of the KLK3 normalized expression levels of the combination of one or more of DLX1, HOXC6, and TDRD1. Treatment for prostate cancer may be administered based on the expression levels of one or more of DLX1, HOXC6, and TDRD1.
1. A method comprising:
(a) reacting a nucleic acid isolated from urine of a patient with a reagent composition that comprises polynucleotide reagents for detecting levels of DLX1 mRNA, HOXC6 mRNA, and KLK3 mRNA in the nucleic acid sample; and
(b) detecting the levels of DLX1 mRNA, HOXC6 mRNA, and KLK3 mRNA in the nucleic acid sample, wherein the polynucleotide reagents for detecting levels of DLX1 mRNA, HOXC6 mRNA, and KLK3 mRNA in the nucleic acid sample comprise a pair of oligonucleotides for amplifying reverse transcribed mRNA for each of the genes DLX1, HOXC6 and KLK3.
2. The method according to claim 1 , wherein the reagent composition further comprises polynucleotide reagents for detecting levels of TDRD1 mRNA in the nucleic acid sample, and the method further comprises detecting the levels of TDRD1 mRNA in the nucleic acid sample.
3. The method according to claim 1 , further comprising performing a biopsy of prostate tissue from the patient.
4. The method according to claim 1 , further comprising administering treatment for aggressive prostate cancer.
5. The method according to claim 4 , wherein the treatment for prostate cancer comprises performing surgery, administering radiation therapy, administering radiopharmaceutical therapy, administering hormone therapy, administering chemotherapy, administering biologic therapy, administering bisphosphonate therapy, administering cryotherapy, administering high-intensity focused ultrasound therapy, administering proton beam radiation therapy, or a combination thereof.
6. The method according to claim 1 , further comprising:
(a) reacting a serum sample from the patient with a reagent composition that comprises components for detecting levels of prostate-specific antigen (sPSA) in the serum sample;
(b) detecting the levels of sPSA in the serum sample.
7. The method accordingly to claim 1 , wherein the urine sample is a first voided urine sample collected after a digital rectal examination.
8. The method accordingly to claim 1 , further comprising isolating the nucleic acid sample from urine of the patient.